Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study
Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study Lee, D., Rodrigues, K., Rana, M., Kozy, K., Salazar, S., Jensen, A., Desai, M., Mallampet, J., Lohman, C., Huang, Y., Kang, X., Tian, F., Mutter, J., Phillips, N., Schweitzer, C., Cheema, F., Mikkilineni, L., Rezvani, A., Johnston, L., Shizuru, J., Meyer, E., Lowsky, R., Weng, W., Smith, M., Bharadwaj, S., Negrin, R., Sidana, S., Muffly, L., Sahaf, B., Natkunam, Y., Shen, R., Frank, M., Mackall, C., Good, Z., Alizadeh, A., Miklos, D., Dahiya, S. ELSEVIER. 2025: 671-672View details for DOI 10.1182/blood-2025-671
View details for Web of Science ID 001659056200022